Veralox Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 14

Veralox Therapeutics General Information

Description

Developer of small molecule therapeutics designed to target heparin-induced thrombocytopenia and thrombosis. The company's therapeutics focus on new treatment paradigms and improved outcomes for patients based on the understanding of the molecular mechanisms of diabetes diseases, enabling patients to achieve complete recovery from diabetes.

Contact Information

Website
www.veralox.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4539 Metropolitan Court
  • Frederick, MD 21704
  • United States
+1 (301)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 4539 Metropolitan Court
  • Frederick, MD 21704
  • United States
+1 (301)

Veralox Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Veralox Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 01-Jan-2026 Completed Generating Revenue
5. Accelerator/Incubator Completed Generating Revenue
4. Later Stage VC 23-Sep-2025 Completed Generating Revenue
3. Later Stage VC (Series B) 21-Jun-2023 Completed Clinical Trials - General
2. Early Stage VC (Series A) 10-Jun-2021 $16.6M $16.6M Completed Clinical Trials - General
1. Grant 18-Oct-2018 $319K Completed Clinical Trials - General
To view Veralox Therapeutics’s complete valuation and funding history, request access »

Veralox Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A
To view Veralox Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Veralox Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small molecule therapeutics designed to target heparin-induced thrombocytopenia and thrombosis. The company
Drug Discovery
Frederick, MD
18 As of 2023

Pasadena, CA
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Veralox Therapeutics Competitors (26)

One of Veralox Therapeutics’s 26 competitors is Meditope Biosciences, a Formerly VC-backed company based in Pasadena, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Meditope Biosciences Formerly VC-backed Pasadena, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
IDEAYA Biosciences Formerly VC-backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Precigen Formerly VC-backed Germantown, MD
You’re viewing 5 of 26 competitors. Get the full list »

Veralox Therapeutics Patents

Veralox Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025207887-A1 Methods for treating heparin-induced thrombocytopenia Pending 27-Mar-2024
AU-2024312215-A1 Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases Pending 22-Jun-2023
EP-4731206-A2 Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases Pending 22-Jun-2023
WO-2024264032-A2 Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases Inactive 22-Jun-2023
WO-2024264032-A3 Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases Inactive 22-Jun-2023 C07D417/12
To view Veralox Therapeutics’s complete patent history, request access »

Veralox Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Veralox Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Pappas Capital Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
Alumni Ventures Venture Capital Minority
Genesys Capital Venture Capital Minority
Point Field Partners Family Office Minority
You’re viewing 5 of 14 investors. Get the full list »

Veralox Therapeutics FAQs

  • When was Veralox Therapeutics founded?

    Veralox Therapeutics was founded in 2017.

  • Where is Veralox Therapeutics headquartered?

    Veralox Therapeutics is headquartered in Frederick, MD.

  • What is the size of Veralox Therapeutics?

    Veralox Therapeutics has 18 total employees.

  • What industry is Veralox Therapeutics in?

    Veralox Therapeutics’s primary industry is Drug Discovery.

  • Is Veralox Therapeutics a private or public company?

    Veralox Therapeutics is a Private company.

  • What is Veralox Therapeutics’s current revenue?

    The current revenue for Veralox Therapeutics is .

  • How much funding has Veralox Therapeutics raised over time?

    Veralox Therapeutics has raised $41.2M.

  • Who are Veralox Therapeutics’s investors?

    Pappas Capital, Alexandria Venture Investments, Alumni Ventures, Genesys Capital, and Point Field Partners are 5 of 14 investors who have invested in Veralox Therapeutics.

  • Who are Veralox Therapeutics’s competitors?

    Meditope Biosciences, Inovio Pharmaceuticals, IDEAYA Biosciences, Adaptimmune Therapeutics, and Precigen are some of the 26 competitors of Veralox Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process